Histone Deacetylase Inhibitors Facilitate Dihydroartemisinin-induced Apoptosis in Liver Cancer in Vitro and in Vivo

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2012 Jul 5

PMID 22761917

Citations 17

Authors

Chris Zhiyi Zhang

Yinghua Pan

Yun Cao

Paul B S Lai

Lili Liu

George Gong Chen

Jingping Yun

Affiliations

Soon will be listed here.

Abstract

Liver cancer ranks in prevalence and mortality among top five cancers worldwide. Accumulating interests have been focused in developing new strategies for liver cancer treatment. We have previously showed that dihydroartemisinin (DHA) exhibited antitumor activity towards liver cancer. In this study, we demonstrated that histone deacetylase inhibitors (HDACi) significantly augmented the antineoplastic effect of DHA via increasing apoptosis in vitro and in vivo. Inhibition of ERK phosphorylation contributed to DHA-induced apoptosis, due to the fact that inhibitor of ERK phosphorylation (PD98059) increased DHA-induced apoptosis. Compared with DHA alone, the combined treatment with DHA and HDACi reduced mitochondria membrane potential, released cytochrome c into cytoplasm, increased p53 and Bak, decreased Mcl-1 and p-ERK, activated caspase 3 and PARP, and induced apoptotic cells. Furthermore, we showed that HDACi pretreatment facilitated DHA-induced apoptosis. In Hep G2-xenograft carrying nude mice, the intraperitoneal injection of DHA and SAHA resulted in significant inhibition of xenograft tumors. Results of TUNEL and H&E staining showed more apoptosis induced by combined treatment. Immunohistochemistry data revealed the activation of PARP, and the decrease of Ki-67, p-ERK and Mcl-1. Taken together, our data suggest that the combination of HDACi and DHA offers an antitumor effect on liver cancer, and this combination treatment should be considered as a promising strategy for chemotherapy.

Citing Articles

Mitoepigenetics pathways and natural compounds: a dual approach to combatting hepatocellular carcinoma.

Hatawsh A, Al-Haddad R, Okafor U, Diab L, Dekanoidze N, Abdulwahab A Med Oncol. 2024; 41(12):302.

PMID: 39465473 DOI: 10.1007/s12032-024-02538-8.

Dihydroartemisinin suppresses glioma growth by repressing ERRα-mediated mitochondrial biogenesis.

Zhang W, Wang Y, Chen L, Chen H, Qi H, Zheng Y Mol Cell Biochem. 2023; 479(10):2809-2825.

PMID: 38072894 DOI: 10.1007/s11010-023-04892-z.

Anti-malarial drug: the emerging role of artemisinin and its derivatives in liver disease treatment.

Xiong Y, Huang J Chin Med. 2021; 16(1):80.

PMID: 34407830 PMC: 8371597. DOI: 10.1186/s13020-021-00489-0.

Dihydroartemisinin: A Potential Natural Anticancer Drug.

Dai X, Zhang X, Chen W, Chen Y, Zhang Q, Mo S Int J Biol Sci. 2021; 17(2):603-622.

PMID: 33613116 PMC: 7893584. DOI: 10.7150/ijbs.50364.

Synergistic antitumor activity of artesunate and HDAC inhibitors through elevating heme synthesis synergistic upregulation of ALAS1 expression.

Chen C, Chen K, Feng Z, Wen X, Sun H Acta Pharm Sin B. 2019; 9(5):937-951.

PMID: 31649844 PMC: 6804493. DOI: 10.1016/j.apsb.2019.05.001.

References

Zhang C, Chen G, Merchant J, Lai P . Interaction between ZBP-89 and p53 mutants and its contribution to effects of HDACi on hepatocellular carcinoma. Cell Cycle. 2012; 11(2):322-34. PMC: 3293381. DOI: 10.4161/cc.11.2.18758. View

Munster P, Thurn K, Thomas S, Raha P, Lacevic M, Miller A . A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br J Cancer. 2011; 104(12):1828-35. PMC: 3111195. DOI: 10.1038/bjc.2011.156. View

Kretzner L, Scuto A, Dino P, Kowolik C, Wu J, Ventura P . Combining histone deacetylase inhibitor vorinostat with aurora kinase inhibitors enhances lymphoma cell killing with repression of c-Myc, hTERT, and microRNA levels. Cancer Res. 2011; 71(11):3912-20. PMC: 3107377. DOI: 10.1158/0008-5472.CAN-10-2259. View

Tsochatzis E, Germani G, Burroughs A . Transarterial chemoembolization, transarterial chemotherapy, and intra-arterial chemotherapy for hepatocellular carcinoma treatment. Semin Oncol. 2010; 37(2):89-93. DOI: 10.1053/j.seminoncol.2010.03.007. View

Booy E, Henson E, Gibson S . Epidermal growth factor regulates Mcl-1 expression through the MAPK-Elk-1 signalling pathway contributing to cell survival in breast cancer. Oncogene. 2011; 30(20):2367-78. PMC: 3145838. DOI: 10.1038/onc.2010.616. View

Jazirehi A, Vega M, Chatterjee D, Goodglick L, Bonavida B . Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by Rituximab. Cancer Res. 2004; 64(19):7117-26. DOI: 10.1158/0008-5472.CAN-03-3500. View

Lu J, Meng L, Shankavaram U, Zhu C, Tong L, Chen G . Dihydroartemisinin accelerates c-MYC oncoprotein degradation and induces apoptosis in c-MYC-overexpressing tumor cells. Biochem Pharmacol. 2010; 80(1):22-30. DOI: 10.1016/j.bcp.2010.02.016. View

Willoughby Sr J, Sundar S, Cheung M, Tin A, Modiano J, Firestone G . Artemisinin blocks prostate cancer growth and cell cycle progression by disrupting Sp1 interactions with the cyclin-dependent kinase-4 (CDK4) promoter and inhibiting CDK4 gene expression. J Biol Chem. 2008; 284(4):2203-13. PMC: 2629082. DOI: 10.1074/jbc.M804491200. View

Gould J, Kenney P, Rieger-Christ K, Silva Neto B, Wszolek M, LaVoie A . Identification of tumor and invasion suppressor gene modulators in bladder cancer by different classes of histone deacetylase inhibitors using reverse phase protein arrays. J Urol. 2010; 183(6):2395-402. DOI: 10.1016/j.juro.2010.02.004. View

10.

Ehses J, Pelech S, Pederson R, McIntosh C . Glucose-dependent insulinotropic polypeptide activates the Raf-Mek1/2-ERK1/2 module via a cyclic AMP/cAMP-dependent protein kinase/Rap1-mediated pathway. J Biol Chem. 2002; 277(40):37088-97. DOI: 10.1074/jbc.M205055200. View

11.

Zhang C, Zhang H, Chen G, Lai P . Trichostatin A sensitizes HBx-expressing liver cancer cells to etoposide treatment. Apoptosis. 2011; 16(7):683-95. DOI: 10.1007/s10495-011-0597-x. View

12.

Xu W, Parmigiani R, Marks P . Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene. 2007; 26(37):5541-52. DOI: 10.1038/sj.onc.1210620. View

13.

Molife L, Attard G, Fong P, Karavasilis V, Reid A, Patterson S . Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC). Ann Oncol. 2009; 21(1):109-13. DOI: 10.1093/annonc/mdp270. View

14.

Marks P, Xu W . Histone deacetylase inhibitors: Potential in cancer therapy. J Cell Biochem. 2009; 107(4):600-8. PMC: 2766855. DOI: 10.1002/jcb.22185. View

15.

Erichsen R, Jepsen P, Jacobsen J, Norgaard M, Vilstrup H, Sorensen H . Time trends in incidence and prognosis of primary liver cancer and liver metastases of unknown origin in a Danish region, 1985-2004. Eur J Gastroenterol Hepatol. 2008; 20(2):104-10. DOI: 10.1097/MEG.0b013e3282f17517. View

16.

Chen T, Li M, Zhang R, Wang H . Dihydroartemisinin induces apoptosis and sensitizes human ovarian cancer cells to carboplatin therapy. J Cell Mol Med. 2008; 13(7):1358-70. PMC: 4496149. DOI: 10.1111/j.1582-4934.2008.00360.x. View

17.

Kim H, Kim C, Lee J, Jang S, Hwang J, Ro S . CG0006, a novel histone deacetylase inhibitor, induces breast cancer cell death via histone-acetylation and chaperone-disrupting pathways independent of ER status. Breast Cancer Res Treat. 2010; 130(2):365-75. DOI: 10.1007/s10549-010-1310-4. View

18.

Dalgard C, Van Quill K, OBrien J . Evaluation of the in vitro and in vivo antitumor activity of histone deacetylase inhibitors for the therapy of retinoblastoma. Clin Cancer Res. 2008; 14(10):3113-23. DOI: 10.1158/1078-0432.CCR-07-4836. View

19.

Calvino E, Estan M, Simon G, Sancho P, Boyano-Adanez M, de Blas E . Increased apoptotic efficacy of lonidamine plus arsenic trioxide combination in human leukemia cells. Reactive oxygen species generation and defensive protein kinase (MEK/ERK, Akt/mTOR) modulation. Biochem Pharmacol. 2011; 82(11):1619-29. DOI: 10.1016/j.bcp.2011.08.017. View

20.

Lane A, Chabner B . Histone deacetylase inhibitors in cancer therapy. J Clin Oncol. 2009; 27(32):5459-68. DOI: 10.1200/JCO.2009.22.1291. View